Article

Understanding the pathogenesis of immune checkpoint inhibitor-induced hepatitis

2020-01-01

Abstract excerpt

Background: Checkpoint inhibitors (CPIs) targeting cytotoxic T lymphocyte antigen- 4 (CTLA-4) and programmed cell death-1 (PD-1) are a novel class of cancer treatments, which stimulate anti-tumour immune responses. CPI treatment is frequently complicated by immune-related adverse events (irAE), including CPI- induced hepatitis (CPI-Hep), which represents one of the most common toxicities. This is a critical burden...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f255733-9824-5774-bd52-e58b518ada14
DOI: 10.25560/85786

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Understanding the pathogenesis of immune checkpoint inhibitor-induced hepatitisDOI 10.25560/85786Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read

Immune Microenvironment and Clinical Significance of PD1 Expression in Hepatocellular Carcinoma PatientsSemantic proximity Read

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.Semantic proximity Read

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Semantic proximity Read

PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcomeSemantic proximity Read

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarksSemantic proximity Read

Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.Semantic proximity Read

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseSemantic proximity Read